Raptor Pharmaceutical Inc

Type: Company

Name: Raptor Pharmaceutical Inc

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Companies to Watch: Affymax Inc., Raptor Pharmaceutical Corp.

Affymax Inc. Going Concern Affymax said its "limited resources and funds" have forced it to weigh all of its strategic alternatives, including "further restructuring activities, wind-down of operations or even bankruptcy proceedings." In a ... ... [Published Dow Jones DBR Small Cap Alert - May 13 2013]

Entities: Affymax Inc, Raptor Pharmaceutical Inc, Bankruptcy

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Walt Disney Company

Raptor to relocate headquarters to Hamilton

NOVATO — Raptor Pharmaceutical Corp. (Nasdaq: RPTP), after steadily growing its pipeline over the past 12 months, will relocate its corporate headquarters to a nearly 31,000-square-foot space at 7 Hamilton Landing, a space formerly occupied by Walt Disney ... [Published North Bay Business Journal - May 13 2013]

Entities: PROCYSBI, Research & Development, Imagemovers Digital, Walt Disney Company

First reported May 09 2013 - Updated May 09 2013 - 2 reports

Raptor Pharmaceutical Inc. (RPTP) Reports First Quarter Calendar Year 2013 Financial Results

Staying up-to-date has never been simpler. Sign up for the today! NOVATO, Calif., May 8, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Raptor or the Company) (Nasdaq:RPTP) today reported financial results for its first quarter ended March 31, ... [Published BioSpace - May 09 2013]

Entities: Raptor Pharmaceutical Inc

First reported May 08 2013 - Updated May 09 2013 - 3 reports

Raptor first-quarter net loss expands 13% as R&D costs double

NOVATO — Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today reported its first-quarter net loss expanded by 13.6 percent from a year before.Net loss was $15.9 million, or 30 cents per share, for the quarter ended March 31, compared with $14 million a year ... [Published North Bay Business Journal - May 09 2013]

Entities: PROCYSBI, Research & Development, Novato (United States)

First reported May 08 2013 - Updated May 08 2013 - 2 reports

3 Healthcare Stock Stories For Tuesday Investment Wellness

Cubist Pharmaceuticals ( NASDAQ: CBST ): Closing price $47.63On Tuesday, Cubist said that the FDA awarded its late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously-granted Qualified Infectious Disease Product ... [Published Wall St. Cheat Sheet - May 08 2013]

Entities: Health Care, Rett Syndrome, GW Pharmaceuticals PLC, Sativex, Raptor Pharmaceutical Inc

First reported May 07 2013 - Updated May 07 2013 - 4 reports

Raptor Pharmaceutical Inc. (RPTP) Licenses Intellectual Property for Rett Syndrome From French Research Institutes

Staying up-to-date has never been simpler. Sign up for the today! NOVATO, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced that it has licensed pending patents related to the use of cysteamine for the treatment ... [Published BioSpace - May 07 2013]

Entities: Rett Syndrome, Raptor Pharmaceutical Inc, Intellectual Property

First reported May 02 2013 - Updated May 02 2013 - 2 reports

Synacor Inc

5 Stocks Under $10 Set to Surge

Tickers in this article: AXDX BCRX DRWI NEPT PSDV RPTPMADISON, Wis. (Stockpickr) -- There isn't a day that goes by on Wall Street when certain stocks trading for $10 a share or less don't experience massive spikes higher. Traders savvy enough to follow ... [Published Delco Times - May 02 2013]

Entities: Moving Average, Stocks, MediciNova Inc, Synacor Inc, James River Coal Company

First reported May 01 2013 - Updated May 02 2013 - 12 reports

Drug for rare kidney disorder approved thanks to parents' efforts

(HealthDay News) — A new drug to treat a rare and deadly inherited kidney disorder has been approved by the U.S. Food and Drug Administration, and the efforts of one patient's parents may have played a key role.The drug Procysbi is for nephropathic cystinosis. ... [Published BabyCenter - May 02 2013]

Entities: PROCYSBI, Cystagon, Kidney

First reported May 02 2013 - Updated May 02 2013 - 2 reports

GLAXOSMITHKLINE PLC: GSK, AZN, KERX, and RPTP Early Briefing and Review

StockCall.com Provides Stock Research on GlaxoSmithKline plc, AstraZeneca PLC, Keryx Biopharmaceuticals Inc., and Raptor Pharmaceuticals Corp.New York City, New York -- (May 02, 2013)Major drug manufacturers have reported their financial results for the ... [Published 4 Traders - May 02 2013]

Entities: GlaxoSmithKline plc, Keryx Biopharmaceuticals Inc, Raptor Pharmaceutical Inc

First reported May 02 2013 - Updated May 02 2013 - 2 reports

Raptor Pharmaceutical Downgraded by Wedbush to Neutral (RPTP)

Raptor Pharmaceutical (NASDAQ: RPTP)Shares of Raptor Pharmaceutical (NASDAQ: RPTP) opened at 6.68 on Thursday. Raptor Pharmaceutical has a 52 week low of $4.35 and a 52 week high of $6.71. The stock's 50-day moving average is currently $5.7. The company's ... [Published American Banking News - May 02 2013]

Entities: Raptor Pharmaceutical Inc, TorreyPines Therapeutics Inc, Leerink Swann & Co Inc

First reported May 01 2013 - Updated May 02 2013 - 2 reports

Raptor Pharmaceutical PT Raised to $14.00 (RPTP)

Analysts at Canaccord Genuity upped their price target on shares of Raptor Pharmaceutical (NASDAQ: RPTP)Separately, analysts at Leerink Swann raised their price target on shares of Raptor Pharmaceutical from $9.00 to $12.00 in a research note to investors ... [Published American Banking News - Stock Ratings - May 02 2013]

Entities: Raptor Pharmaceutical Inc, TorreyPines Therapeutics Inc, Leerink Swann & Co Inc, Canaccord Genuity Corp

First reported Apr 30 2013 - Updated May 01 2013 - 16 reports

Raptor Pharmaceutical awarded FDA approval for PROCYSBI

6 minutes ago, 8:19am (ET) 05/01/2013 M2Biotechnology company Raptor Pharmaceutical Corp (NasdaqGM:RPTP) reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for PROCYSBI (cysteamine bitartrate) delayed release capsules ... [Published Zecco - May 01 2013]

Entities: PROCYSBI, Raptor Pharmaceutical Inc, Cystine, Kidney, disease progression

Quotes

Affymax Inc. Going Concern Affymax said its "limited resources and funds" have forced it to weigh all of its strategic alternatives, including "further restructuring activities, wind-down of operations or even bankruptcy proceedings." In a

Companies to Watch: Affymax Inc., Raptor Pharmaceutical Corp. [Published Dow Jones DBR Small Cap Alert - May 13 2013]

...the U S and getting the product to cystinosis patients as soon as possible," said Christopher M Starr, Ph D , Raptor's chief executive officer. $ "We are thankful to the cystinosis community, physicians, investors and our employees for bringing the development of PROCYSBITM to fruition."

Raptor Pharmaceutical Reports First Quarter Calendar Year 2013 Financial Results [Published Morningstar.com - May 08 2013]

...There was no internet, and we had limited resources," Nancy Stack said. "Through the foundation, we have worked to develop and fund better treatments, and that is what Procysbi is. It is the closest thing to a cure."

Novato's Raptor Pharmaceutical Nabs FDA Approval for New Drug, Making SoCal Woman's Birthday Wish [Published Novato Patch - May 07 2013]

...as well as neurodegenerative conditions such as Huntington's disease and Parkinson's disease," stated Ted Daley, chief business officer of Raptor. "We are excited to leverage our cysteamine expertise and eagerly anticipate moving forward in the potential development of a novel therapy for patients with Rett syndrome."

Raptor Pharmaceutical Licenses Intellectual Property for Ret. . . [Published Equities.com - May 07 2013]

More Content

sort by: Date \| Relevance
Companies to Watch: Affymax Inc., Raptor Pharma... [Published Dow Jones DBR Small Cap Alert - May 13 2013]
Raptor to relocate headquarters to Hamilton [Published North Bay Business Journal - May 13 2013]
Leases and sales: Week of May 13, 2013 [Published North Bay Business Journal - May 13 2013]
Miss Any of Our Most Popular Stories? Hotlist f... [Published Novato Patch - May 12 2013]
Raptor Pharmaceutical Inc. (RPTP) Reports First... [Published BioSpace - May 09 2013]
Raptor Pharmaceutical Inc. Reports First Quarte... [Published BioSpace - May 09 2013]
Raptor Pharmaceuticals (RPTP): Q1 EPS of $-0.30... [Published Seeking Alpha - May 09 2013]
Raptor first-quarter net loss expands 13% as R&... [Published North Bay Business Journal - May 09 2013]
U.S./Canada daily earnings hits & misses May 8 ... [Published Globe and Mail - May 08 2013]
Raptor Pharmaceutical Reports First Quarter Cal... [Published Morningstar.com - May 08 2013]
Raptor Pharmaceutical Reports First Quarter Cal... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Raptor Pharmaceutical Reports First Quarter Cal... [Published Interest!ALERT - May 08 2013]
3 Healthcare Stock Stories For Tuesday Investme... [Published Wall St. Cheat Sheet - May 08 2013]
3 Healthcare Stock Stories For Tuesday Investme... [Published Wall St. Cheat Sheet - May 08 2013]
Raptor Pharmaceutical Inc. (RPTP) Licenses Inte... [Published BioSpace - May 07 2013]
Novato's Raptor Pharmaceutical Nabs FDA Approva... [Published Novato Patch - May 07 2013]
Raptor Pharmaceutical Licenses Intellectual Pro... [Published Equities.com - May 07 2013]
Raptor Pharmaceutical Licenses Intellectual Pro... [Published GlobeNewswire: Acquisitions News - May 07 2013]
Raptor Pharmaceutical Licenses Intellectual Pro... [Published Morningstar.com - May 07 2013]
Raptor Pharmaceutical Licenses Intellectual Pro... [Published Benzinga.com - May 07 2013]
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013]
Merck & Co., Inc. (MRK), AVEO Pharmaceuticals, ... [Published InsiderMonkey.com - May 04 2013]
US FDA approves Raptor Pharma's Procysbi for tr... [Published PharmaBiz - May 04 2013]
Raptor Pharma's Procysbi receives FDA approval ... [Published Center Watch - May 04 2013]
Weekly Roundup 5-3-13 [Published Eye on FDA - May 03 2013]
CDM Girl's Birthday Wish Spurs 'Life-Saving' Me... [Published Newport Beach Patch - May 03 2013]
Stocks Buzz: Kraton Performance Polymers Inc, R... [Published SBWire - May 03 2013]
MARKET PULSE-Apple, Gilead, Aveo, GM, Visa, Fac... [Published CNBC - May 02 2013]
5 Stocks Under $10 Set to Surge [Published Delco Times - May 02 2013]
5 Stocks Under $10 Set to Surge [Published AdvisorSource.com - May 02 2013]

Blogs

sort by: Date \| Relevance
3 Healthcare Stock Stories For Tuesday Investme... [Published Wall St. Cheat Sheet - May 08 2013] Cubist Pharmaceuticals ( NASDAQ: CBST ): Closing price $47.63On Tuesday, Cubist said that the FDA awarded its late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously-granted Qualified Infectious Disease Product ...
3 Healthcare Stock Stories For Tuesday Investme... [Published Wall St. Cheat Sheet - May 08 2013] Cubist Pharmaceuticals ( NASDAQ: CBST ): Closing price $47.63 On Tuesday, Cubist said that the FDA awarded its late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously-granted Qualified Infectious Disease ...
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013] In the first half of 2013, two drugs will have launched in the US priced at $250,000 per patient annually: Both address serious, ultra-rare diseases and are backed by KOLs and patients. But the similarities stop there. Three months into its launch, ...
Weekly Roundup 5-3-13 [Published Eye on FDA - May 03 2013] The grass is not greener on my side, mainly because it is mostly not there. The lawn, if you want to call it that, looks like it needs a lot of attention – probably more than I have to give it. Still, that did not stop me from mowing what was ...
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: US... [Published Proactiveinvestors United Kingdom website - May 02 2013] US equities look to open in minor positive territory, erasing some of the large losses seen during yesterday's session. Focus today has been on the ECB rate decision where the central bank cut their main refi rate by 25bps and the marginal lending rate ...

Press Releases

sort by: Date \| Relevance
Raptor Pharmaceutical Reports First Quarter Cal... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Raptor Pharmaceutical Licenses Intellectual Pro... [Published GlobeNewswire: Acquisitions News - May 07 2013]
Multimedia Now Available: Raptor Pharmaceutical... [Published PR Newswire: Policy & Public Interest - May 01 2013]
Raptor Pharmaceuticals PROCYSBI™ erhält FDA-Zul... [Published PR Newswire: Policy & Public Interest - May 01 2013]
PROCYSBI ™ de Raptor Pharmaceutical autorisé pa... [Published PR Newswire: Health - May 01 2013]